Research programme: phosphodiesterase inhibitors - ICOS

Drug Profile

Research programme: phosphodiesterase inhibitors - ICOS

Alternative Names: PDE inhibitors research programme ICOS; Phosphodiesterase inhibitors research programme - ICOS

Latest Information Update: 08 Feb 2007

Price : $50

At a glance

  • Originator ICOS Corporation
  • Class
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Parkinson's disease; Urinary incontinence

Most Recent Events

  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 15 Sep 2005 This programme is still in active development
  • 08 Jul 2003 Preclinical trials in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top